Use of a Self-Delivering Anti-CCL3 FANA Oligonucleotide as an Innovative Approach to Target Inflammation after Spinal Cord Injury.
eNeuro. 2021 Mar 11;8(2):ENEURO.0338-20.2021. doi: 10.1523/ENEURO.0338-20.2021. Print 2021 Mar-Apr.
eNeuro. 2021.
PMID: 33632814
Free PMC article.